drugset

drugset / Trial / NCT03409588

Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty

NCT03409588 ↗

Phase 2 Completed 10 enrolled University of Colorado, Denver Bayer · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an open label study of Riociguat in patients with continued exercise intolerance at least 6 months following pulmonary endarterectomy (PEA).

Timeline

Start: 2018-06-13
Primary completion: 2026-01-26
Completion: 2026-01-26

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Riociguat	Other / unclassified	2.5 mg	Oral

Indications